Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
July 2012
Features
Editorial
Hydrocodone Rescheduling Amendment and Pipeline Products on the Horizon
A controversial bill to change the classification of the opioid hydrocodone from Schedule III to Schedule II might help decrease the incidence of drug abuse through stricter regulation of Schedule II products, or, as some groups claim, it might hinder access for patients with legitimate prescriptions.
Jennifer A. Gershman, PharmD, CPh; and Andrea D. Fass, PharmD
Therapy for Stable Angina in Women
Mortality rates for cardiovascular disease are higher in women than in men, but studies of women have been conducted less frequently. Current pharmacological and nonpharmacological treatment options for women with stable angina are reviewed.
Raheleh Sarbaziha, MD; Tara Sedlak, MD; Chrisandra Shufelt, MD, MS; Puja K. Mehta, MD; and C. Noel Bairey Merz, MD
Controversies in Practice
Hydroxyprogesterone Caproate Injection (Makena) One Year Later
To Compound or Not to Compound—That Is the Question
Preterm births have increased by 27% over the last decade in the U.S. The main ingredient in Makena, 17P, is less expensive at compounding pharmacies, but this method is not FDA-approved. The authors discuss the quality, safety, and use of Makena and compounded 17P; the potential for liability; cost considerations; and recommended restrictions for the product’s use.
Yesha Patel, PharmD; and Martha M. Rumore, PharmD, JD
Continuing Education Credit
A Review of Abuse-Deterrent Opioids for Chronic Nonmalignant Pain
Chronic nonmalignant pain, which affects millions of people, is the most common reason patients seek medical care. Both current and potential opioid analgesics are discussed, along with new technologies used to prevent abuse.
Robin Moorman-Li, PharmD, BCACP; Carol A. Motycka, PharmD, BCACP; Lisa D. Inge, PharmD, BCPS, BCACP, AAHIVE; Jocelyn Myrand Congdon, PharmD; Susan Hobson, PharmD; and Brian Pokropski, PharmD
Departments
Medication Errors
Physical Environments That Promote Safe Medication Use
The physical design of an organization’s workspace can enhance or diminish patient safety.
Matthew Grissinger, RPh, FaScP
Prescription: Washington
FDA's New Authority on Drug Shortages
Drug companies may be required to report shortages sooner, but the FDA legislation still lacks power.
Stephen Barlas
New Drugs/Drug News/New Medical Devices
FDA approvals, drug indications, and updates
Pharmaceutical Approval Update
Tazarotene (Fabior Foam) for acne; estradiol valerate and estradiol valerate/dienogest (Natazia) for heavy menstrual bleeding; and taliglucerase alfa (Elelyso) for Gaucher’s disease
Marvin M. Goldenberg, PhD, RPh, MS
Drug Forecast
Fospropofol Disodium (Lusedra) Injection for Anesthesia-Care Sedation
A Clinical Review
Fospropofol disodium (Lusedra) for anesthesia sedation
Ramy Boules, PharmD; Andrew Szkiladz, PharmD; and Anna Nogid, BS, PharmD, BCPS
